Company Overview and News
There has been an inversion in the TIPS market as the nominal yield curve flattens near cycle lows.
For the third consecutive week, investors were net purchasers of overall fund assets (including those of conventional funds and ETFs), injecting $20.5 billion for Thomson Reuters Lipper's fund-flows week ended August 8, 2018. But, despite continued strong corporate earnings and a fair nonfarm-payrolls report during the week, fund investors were net redeemers of equity funds (-$962 million), while they padded the coffers of money market funds (+$16.
IEF IEMG AAPL TIP IWM
Thomson Reuters Lipper’s fund asset groups (including both mutual funds and ETFs) had net inflows of $403 million for the fund-flows week ended Wednesday, August 1. Equity funds (+$2.1 billion) accounted for the lion’s share of the net-positive flows, while money market funds contributed $344 million to the total. Fixed income funds did not fare as well; both taxable bond funds (-$1.6 billion) and municipal bond funds (-$368 million) both saw net money leave their coffers.
FB AMZN AAPL TIP
Real yields are out of balance with historical norms. A 5-year TIPS is yielding only 13 basis points less than a 30-year TIPS.
Positive returns dominated the first week of trading in July for the major asset classes, based on a set of US-listed exchange-traded products. With the exception of broadly defined commodities, every corner of finanical markets posted gains for the trading week through July 6.
BNPZY VNQI BNPQY TIP BNPQF
Though the volatility is a bit high and there are worries over trade and tariffs, interest-rates and a host of other issues, but the markets are still doing fine.
AGG TIPS TIP JPC
Traditional portfolio strategies for hedging against inflation can be effective during quickly rising or higher than expected inflation, but often provide lackluster or inconsistent returns during periods of low inflation.
BKLN VFH IYF VTIP TIP GLD EV IAU VGT VHT O87 IBB STIP ROBO
U.S. employers added 103,000 new jobs in March, after an upwardly revised 326,000 job gains in February and falling short of market expectations of 193,000 jobs. However, job gains in January have been revised down from 239,000 to 176,000. After revision, total employment gains in January and February were 50,000 less than reported earlier.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TIP / iShares TIPS Bond ETF on message board site Silicon Investor.
as of ET